Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.

Perrino, Matteo; De Pas, Tommaso; Bozzarelli, Silvia; Giordano, Laura; De Vincenzo, Fabio; Conforti, Fabio; Digiacomo, Nunzio; Cordua, Nadia; D'Antonio, Federica; Borea, Federica; Santoro, Armando; Zucali, Paolo Andrea

Perrino, Matteo; De Pas, Tommaso; Bozzarelli, Silvia; Giordano, Laura; De Vincenzo, Fabio; Conforti, Fabio; Digiacomo, Nunzio; Cordua, Nadia; D'Antonio, Federica; Borea, Federica; Santoro, Armando; Zucali, Paolo Andrea.

Affiliation

Perrino M; Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy.
De Pas T; Department of Oncology, IRCCS, European Institute of Oncology, Milan, Italy.
Bozzarelli S; Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy.
Giordano L; Biostatistic Unit, IRCCS, Humanitas Research Hospital, Milan, Italy.
De Vincenzo F; Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy.
Conforti F; Department of Oncology, IRCCS, European Institute of Oncology, Milan, Italy.
Digiacomo N; Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy.
Cordua N; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
D'Antonio F; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Borea F; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Santoro A; Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy.
Zucali PA; Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Cancer ; 128(4): 719-726, 2022 02 15.

Article in En | MEDLINE | ID: mdl-34706060

Subject(s)

Phenylurea Compounds/therapeutic use; Thymoma; Thymus Neoplasms; Disease-Free Survival; Humans; Neoplasm Recurrence, Local/pathology; Pyridines; Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors; Receptors, Fibroblast Growth Factor/antagonists & inhibitors; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors; Thymoma/drug therapy; Thymoma/pathology; Thymus Neoplasms/drug therapy; Thymus Neoplasms/pathology

Key words

activity; phase 2 trial; regorafenib; thymic epithelial tumors; toxicity profile

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Phenylurea Compounds / Thymoma / Thymus Neoplasms Limits: Humans Language: En Journal: Cancer Year: 2022 Type: Article Affiliation country: Italy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google